Janus Henderson Group
ESPR

Janus Henderson Group’s Esperion Therapeutics ESPR Stock Holding History

Janus Henderson Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,767
Closed -$47.5K – 2619
2023
Q1 		$47.5K Buy
29,767
+13,669
+85% +$70.6K ﹤0.01% 2666
2022
Q4 		$100K Buy
+16,098
New +$115K ﹤0.01% 2330
2020
Q1 		– Sell
-3,926
Closed -$234K – 1326
2019
Q4 		$234K Buy
+3,926
New +$177K ﹤0.01% 1380

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Janus Henderson Group's ESPR Position: Q2 2023 in Review

Janus Henderson Group sold out of Esperion Therapeutics (ESPR) in Q2 2023, closing a stake of 29,767 shares — an estimated $47.5K sold.

Janus Henderson Group first reported a position in ESPR in Q4 2019 and held it in 3 quarters. The position peaked at $234K in Q4 2019. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

  • Janus Henderson Group reported no remaining Esperion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Janus Henderson Group sold 29,767 Esperion Therapeutics shares in Q2 2023, an estimated $47.5K.
  • Janus Henderson Group first reported a position in Esperion Therapeutics in Q4 2019 and held it in 3 quarters.
  • Janus Henderson Group's Esperion Therapeutics position peaked at $234K in Q4 2019.
  • 124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.